Idalopirdine falls short in three phase 3 Alzheimer’s trialsJanuary 9, 2018Alzheimer's & CognitionNeurologyGeriatrics
Tau imaging predicts looming cognitive decline in cognitively normal elderlyDecember 26, 2017Alzheimer's & CognitionGeriatricsNeurology
Head injury linked to amyloid deposition decades laterDecember 19, 2017Alzheimer's & CognitionNeurologyGeriatrics
Up to 47 million Americans may have “preclinical” Alzheimer’s disease, study estimatesDecember 13, 2017Alzheimer's & CognitionNeurologyGeriatrics
Intranasal insulin, ketogenic diet may benefit Alzheimer’s patientsDecember 6, 2017DiabetesAlzheimer's & CognitionNeurologyGeriatrics
Retinal changes may reflect brain changes in preclinical Alzheimer’sDecember 4, 2017Alzheimer's & CognitionGeriatricsMental HealthNeurology
Walking has beneficial cognitive effects in amyloid-positive older adultsDecember 3, 2017Alzheimer's & CognitionGeriatricsNeurology
Intepirdine flops in phase 3 study of mild to moderate Alzheimer’s patientsNovember 28, 2017Alzheimer's & CognitionNeurologyGeriatrics
Development of a sigma 1 receptor agonist for Alzheimer’s proceeds based on 2-year phase 2 dataNovember 21, 2017Alzheimer's & CognitionNeurology
Long-term cholinesterase inhibition may slow cognitive decline – and moreNovember 15, 2017Alzheimer's & CognitionNeurologyMental HealthGeriatrics
Pimavanserin found modestly effective in phase 2 Alzheimer’s psychosis studyNovember 14, 2017Alzheimer's & CognitionGeriatricsNeurologyMental Health
Unblinded data show extent of verubecestat’s failure in mild-moderate Alzheimer’sNovember 12, 2017Alzheimer's & CognitionNeurologyGeriatrics
Amyloid imaging changed management for 80% of patients with uncertain dementia diagnosisNovember 9, 2017Alzheimer's & CognitionNeurologyGeriatricsMental Health
New BACE1 study launches in the shadow of verubecestat’s demiseNovember 4, 2017Alzheimer's & CognitionNeurologyGeriatrics
